Pemphigus Patients Receiving Rituximab: Latent Tuberculosis Risk and Diagnostic Concordance Between Tuberculin Skin Test and Interferon‐Gamma Release Assay
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/5595483 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 02.08.2026. Verfasst von Fateme Faramarzirad und 5 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aim Rituximab (RTX) therapy in pemphigus patients necessitates reliable latent tuberculosis (TB) infection (LTBI) screening to prevent reactivation. The tuberculin skin test (TST) and Interferon‐Gamma Release Assay (IGRA) are commonly used, yet discrepancies in their results create uncertainty, particularly in immunocompromised hosts. Evidence regarding their concordance in pemphigus patients undergoing RTX is limited. This study evaluates the agreement between TST and IGRA and explores whether TST alone can serve as an effective LTBI screening tool before RTX treatment.
Methods
A multicenter prospective observational study was conducted on adult pemphigus patients confirmed through biopsy/immunofluorescence. Baseline evaluation included demographic and disease data, IGRA, TST, and chest X‐ray. RTX was given as either 500 mg weekly for 4 weeks or 1000 mg every 2 weeks for two doses. Six months later, IGRA, TST, chest imaging, and clinical TB assessment were repeated. Data were analyzed with SPSS v26, using McNemar’s exact test for paired comparisons, generalized estimating equations for repeated measures within subjects, and Cohen’s kappa (McHugh’s criteria) for test agreement.
Results
Forty‐two patients with pemphigus (92.9% pemphigus vulgaris, 7.1% pemphigus foliaceus; mean age = 51.98 ± 13.47 years; 52.4% female) were followed for a mean duration of 10.1 ± 3.66 months. All had a history of prior BCG vaccination, were asymptomatic for TB at baseline, and demonstrated normal chest radiographs. Four patients (9.8%) were diagnosed with LTBI by IGRA and/or TST and received isoniazid prophylaxis before initiation of RTX therapy. At 6 months post‐RTX, no cases of clinical or radiographic TB were detected. IGRA and TST positivity rates remained unchanged ( p = 1.00), except for one patient who reverted from positive to negative (OR = 1.37). TST results were stable ( p = 1.00). IGRA–TST agreement was moderate before ( κ = 0.64) and after therapy ( κ = 0.79) with no significant directional bias on positivity rate.
Conclusion
RTX treatment in pemphigus patients, following appropriate latent TB screening and preventive therapy, was not associated with TB reactivation. IGRA and TST results remained stable after treatment, with sustained agreement between the tests. These findings support the safety of RTX and the potential for utility of either method for TB screening in BCG‐vaccinated populations in countries with limited resources.
Zitieren
APA
Faramarzirad, F., Tahvildari, A., Namazi, N., Abdollahimajd, F., Al-Zubaidi, N., & Dadkhahfar, S. (2026). Pemphigus Patients Receiving Rituximab: Latent Tuberculosis Risk and Diagnostic Concordance Between Tuberculin Skin Test and Interferon‐Gamma Release Assay. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/5595483
Vancouver
Faramarzirad F, Tahvildari A, Namazi N, Abdollahimajd F, Al-Zubaidi N, Dadkhahfar S. Pemphigus Patients Receiving Rituximab: Latent Tuberculosis Risk and Diagnostic Concordance Between Tuberculin Skin Test and Interferon‐Gamma Release Assay. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/5595483
BibTeX
@article{Faramarzirad2026,
author = {Faramarzirad, Fateme and Tahvildari, Azin and Namazi, Nastaran and Abdollahimajd, Fahimeh and Al-Zubaidi, Nabaa and Dadkhahfar, Sahar},
title = {Pemphigus Patients Receiving Rituximab: Latent Tuberculosis Risk and Diagnostic Concordance Between Tuberculin Skin Test and Interferon‐Gamma Release Assay},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/5595483}
}
EUVIMED